High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients

BMC Cancer

Remco S Derr²  Anneke Q van Hoesel²  Anne Benard²  Inès J Goossens-Beumer²  Anita Sajet²  N Geeske Dekker-Ensink²  Esther M de Kruijf²  Esther Bastiaannet²  Vincent THBM Smit¹  Cornelis JH van de Velde²  Peter JK Kuppen² 

[1] Department of Pathology, LUMC, Leiden, The Netherlands

[2] Department of Surgery, K6-R, Leiden University Medical Center (LUMC), P.O. Box 9600, 2300 RC Leiden, The Netherlands

关键词: SIRT1;    LSD1;    Histone-modifying enzymes;    HDAC2;    Epigenetics;    Clinical outcome;    Breast cancer;    Biomarkers;   

Others  :  1134786
DOI  :  10.1186/1471-2407-14-604

 received in 2014-03-04, accepted in 2014-08-08,  发布年份 2014

【 摘 要 】

Background

Breast cancer is a heterogeneous disease with a highly variable clinical outcome in which both genetic and epigenetic changes have critical roles. We investigated tumor expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in relation with patient survival and tumor relapse in a retrospective cohort of 460 breast cancer patients. Additionally, we correlated expression levels with tumor differentiation and tumor cell proliferation.

Methods

Immunohistochemical staining for LSD1, HDAC2 and SIRT1 was performed on tissue microarrays of tumor and corresponding normal formalin-fixed paraffin-embedded tissues from breast cancer patients. Median nuclear expression levels in tumor tissues were used to divide the patients into low and high expression categories. In combined expression analyses, patients were divided into four subgroups: 1, all enzymes below-median; 2, one enzyme above-median; 3, two enzymes above-median; 4, all three enzymes above-median. The Cox proportional hazard model was used for univariate and multivariate survival analyses. The Pearson Chi-square method was used to assess correlation of combined expression levels with tumor cell proliferation and tumor differentiation.

Results

Expression of LSD1 and SIRT1, but not of HDAC2, was significantly increased in tumor tissues compared to their normal counterparts (both p < 0.001). Multivariate survival analyses identified SIRT1 as independent prognostic factor for relapse-free survival (RFS) with a hazard ratio (HR) of 1.34 (95% CI = 1.04-1.74, p = 0.02). For overall survival (OS), no significant differences were found when the individual enzymes were analyzed. Analyses of combined expression levels of the three histone-modifying enzymes correlated with OS (p = 0.03) and RFS (p = 0.006) with a HR of respectively 1.49 (95% CI = 1.07-2.08) and 1.68 (95% CI = 1.16-2.44) in multivariate analyses and were also related to tumor differentiation (p < 0.001) and tumor cell proliferation (p = 0.002).

Conclusions

When the combined expression levels were analyzed, high expression of LSD1, HDAC2 and SIRT1 showed shorter patient survival time and shorter time to tumor relapse and correlated with poor tumor differentiation and a high level of tumor cell proliferation. Expression of these histone-modifying enzymes might therefore be involved in breast cancer pathogenesis.

【 授权许可】

   
2014 Derr et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
• [2]Marme F, Schneeweiss A: Personalized therapy in breast cancer. Onkologie 2012, 35(Suppl 1):28-33.
• [3]Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG: Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett 2012, 342:213-222.
• [4]Klose RJ, Zhang Y: Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007, 8:307-318.
• [5]Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R: Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol 2012, 12:13. BioMed Central Full Text
• [6]Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
• [7]Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011, 104:1828-1835.
• [8]Liu T, Liu PY, Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009, 69:1702-1705.
• [9]Sung JY, Kim R, Kim JE, Lee J: Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 2010, 101:1738-1744.
• [10]Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011, 42:204-213.
• [11]Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE: Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat 2012, 131:777-789.
• [12]Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y: Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 2013, 34:1196-1207.
• [13]Mulligan P, Yang F, Di SL, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Naar AM: A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell 2011, 42:689-699.
• [14]de Kruijf EM, Engels CC, van de Water W, Bastiaannet E, Smit VT, van de Velde CJ, Liefers GJ, Kuppen PJ: Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat 2013, 142:355-364.
• [15]Federation of Medical Scientific Societies: Code for Proper Secondary Use of Human Tissue in the Netherlands. 43. http://www.federa.org/sites/default/files/bijlagen/coreon/codepropersecondaryuseofhumantissue1_0.pdf webcite
• [16]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391.
• [17]Gu H, Roizman B: Engagement of the lysine-specific demethylase/HDAC1/CoREST/REST complex by herpes simplex virus 1. J Virol 2009, 83:4376-4385.
• [18]Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, Evers BM, Zhou BP: The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J 2010, 29:1803-1816.
• [19]Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009, 28:445-460.
• [20]van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, Bartlett JM: COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011, 125:671-685.
• [21]Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ, Kuppen PJ: The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res Treat 2013, 142:323-339.
• [22]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [23]Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R: Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011, 128:574-586.
• [24]Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denckert C: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013, 13:215. BioMed Central Full Text
• [25]Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekattar R, Bedford MT, Jenuwein T, Berger SL: p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449:105-108.
• [26]Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448.
• [27]Harms KL, Chen X: Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007, 67:3145-3152.